Dacomitinib Beats Gefitinib for EGFR+ NSCLC.
Sign Up to like & getrecommendations! Published in 2017 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2017-089
Abstract: The irreversible EGFR inhibitor dacomitinib reduced the chance of lung cancer progression compared with an older, first-generation EGFR inhibitor, gefitinib, in a phase III trial. As reported at the 2017 American Society of Clinical Oncology… read more here.
Keywords: egfr; gefitinib egfr; egfr inhibitor; dacomitinib ... See more keywords